文献速递心脑血管急症重症综合管理与镇静镇痛

限制性与宽松输血策略对急性心肌梗死合并贫血患者主要心血管事件的影响:REALITY随机临床试验

Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01
一句话结论急性心肌梗死合并贫血患者中,限制性输血策略(血红蛋白≤8 g/dL触发)在30天主要心血管事件上不劣于宽松策略,但置信区间包含可能具有临床重要性的危害。

REALITY试验在法国和西班牙35家医院纳入668例急性心肌梗死且血红蛋白7-10 g/dL的患者,随机接受限制性(血红蛋白≤8 g/dL触发输血,n=342)或宽松性(血红蛋白≤10 g/dL触发,n=324)输血策略。30天主要终点MACE(全因死亡、卒中、再发心梗或缺血驱动的急诊血运重建复合终点)发生率限制性组11.0% vs 宽松组14.0%(差值-3.0%,95%CI -8.4%至2.4%),相对风险0.79(单侧97.5%CI 0.00-1.19),满足预设非劣效界值(上限<1.25)。结论认为限制性策略不劣于宽松策略,但置信区间包含可能具有临床重要性的危害。

要点

  • 急性心梗合并贫血(血红蛋白7-10 g/dL)患者中,限制性输血(血红蛋白≤8 g/dL触发)30天MACE 11.0% vs 宽松性(≤10 g/dL触发)14.0%,差值-3.0%(95%CI -8.4%至2.4%)。
  • 相对风险0.79(单侧97.5%CI 0.00-1.19),满足预设非劣效界值(上限<1.25)。
  • 限制性组35.7%接受输血(共342单位红细胞),宽松组99.7%接受输血(共758单位)。
  • 30天全因死亡限制性组5.6% vs 宽松组7.7%,再发心梗2.1% vs 3.1%,缺血驱动急诊血运重建1.5% vs 1.9%,非致命缺血性卒中两组均为0.6%。
  • 作者结论指出置信区间包含可能具有临床重要性的危害。

适用人群与场景

  • 急性心肌梗死且血红蛋白水平在7至10 g/dL之间的患者,可在心梗指数住院期间任何时间入组。
  • 共668例随机,666例完成30天随访;中位年龄77岁(IQR 69-84),女性281例(42.2%)。

诊断标准与关键阈值

  • 限制性输血策略:血红蛋白≤8 g/dL时触发输血。
  • 宽松性输血策略:血红蛋白≤10 g/dL时触发输血。
  • 非劣效界值:主要终点相对风险的单侧97.5%CI上限<1.25。

处置流程与药物剂量

  • 限制性组:血红蛋白≤8 g/dL触发输血,342例中122例(35.7%)接受输血,共输注342单位浓缩红细胞。
  • 宽松组:血红蛋白≤10 g/dL触发输血,324例中323例(99.7%)接受输血,共输注758单位浓缩红细胞。

研究设计与关键结果

  • 开放标签、非劣效随机试验,在法国和西班牙35家医院进行,纳入668例急性心肌梗死合并贫血(血红蛋白7-10 g/dL)患者。
  • 30天MACE(全因死亡、卒中、再发心梗或缺血驱动的急诊血运重建复合终点):限制性组36例(11.0%,95%CI 7.5%-14.6%)vs 宽松组45例(14.0%,95%CI 10.0%-17.9%),差值-3.0%(95%CI -8.4%至2.4%)。
  • 主要终点相对风险0.79(单侧97.5%CI 0.00-1.19),满足预设非劣效标准。
  • 30天全因死亡:限制性组5.6% vs 宽松组7.7%;再发心梗:2.1% vs 3.1%;缺血驱动急诊血运重建:1.5% vs 1.9%;非致命缺血性卒中:两组均为0.6%。

证据类型、等级与局限

  • 证据类型:开放标签、非劣效随机临床试验(REALITY)。
  • 局限:作者指出置信区间包含可能具有临床重要性的危害。

对床旁实践的改变

  • 在急性心肌梗死合并贫血(血红蛋白7-10 g/dL)患者中,限制性输血策略(血红蛋白≤8 g/dL触发)30天MACE不劣于宽松策略(≤10 g/dL触发),但置信区间包含可能具有临床重要性的危害。

指南或共识出处

  • REALITY随机临床试验,ClinicalTrials.gov注册号NCT02648113。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The optimal transfusion strategy in patients with acute myocardial infarction and anemia is unclear.

OBJECTIVE: To determine whether a restrictive transfusion strategy would be clinically noninferior to a liberal strategy.

DESIGN, SETTING, AND PARTICIPANTS: Open-label, noninferiority, randomized trial conducted in 35 hospitals in France and Spain including 668 patients with myocardial infarction and hemoglobin level between 7 and 10 g/dL. Enrollment could be considered at any time during the index admission for myocardial infarction. The first participant was enrolled in March 2016 and the last was enrolled in September 2019. The final 30-day follow-up was accrued in November 2019.

INTERVENTIONS: Patients were randomly assigned to undergo a restrictive (transfusion triggered by hemoglobin ≤8; n = 342) or a liberal (transfusion triggered by hemoglobin ≤10 g/dL; n = 324) transfusion strategy.

MAIN OUTCOMES AND MEASURES: The primary clinical outcome was major adverse cardiovascular events (MACE; composite of all-cause death, stroke, recurrent myocardial infarction, or emergency revascularization prompted by ischemia) at 30 days. Noninferiority required that the upper bound of the 1-sided 97.5% CI for the relative risk of the primary outcome be less than 1.25. The secondary outcomes included the individual components of the primary outcome.

RESULTS: Among 668 patients who were randomized, 666 patients (median [interquartile range] age, 77 [69-84] years; 281 [42.2%] women) completed the 30-day follow-up, including 342 in the restrictive transfusion group (122 [35.7%] received transfusion; 342 total units of packed red blood cells transfused) and 324 in the liberal transfusion group (323 [99.7%] received transfusion; 758 total units transfused). At 30 days, MACE occurred in 36 patients (11.0% [95% CI, 7.5%-14.6%]) in the restrictive group and in 45 patients (14.0% [95% CI, 10.0%-17.9%]) in the liberal group (difference, -3.0% [95% CI, -8.4% to 2.4%]). The relative risk of the primary outcome was 0.79 (1-sided 97.5% CI, 0.00-1.19), meeting the prespecified noninferiority criterion. In the restrictive vs liberal group, all-cause death occurred in 5.6% vs 7.7% of patients, recurrent myocardial infarction occurred in 2.1% vs 3.1%, emergency revascularization prompted by ischemia occurred in 1.5% vs 1.9%, and nonfatal ischemic stroke occurred in 0.6% of patients in both groups.

CONCLUSIONS AND RELEVANCE: Among patients with acute myocardial infarction and anemia, a restrictive compared with a liberal transfusion strategy resulted in a noninferior rate of MACE after 30 days. However, the CI included what may be a clinically important harm.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02648113.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Ducrocq G, Gonzalez-Juanatey JR, Puymirat E, et al. Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial. JAMA. 2021. PMID: 33560322. doi:10.1001/jama.2021.0135

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。